GlassScriptPhysician profile
Saman B Chubineh
NPI 1861654980
$10,769.60
in general payments reported to CMS, 2019-2025
25 companies · $2,783 in 2025
The $2,783 reported for 2025 was more than what 86% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $284 · 2020: $351 · 2021: $851 · 2022: $1,243 · 2023: $2,215 · 2024: $3,042 · 2025: $2,783.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,040.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,040.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $3,350.64 | 2019-2025 | Tremfya, Stelara |
| Abbvie INC. | $1,329.32 | 2019-2025 | Linzess, Viberzi, Rinvoq |
| Qol Medical, LLC | $1,004.23 | 2021-2025 | Sucraid, Sucraid |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $962.58 | 2022-2025 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $786.28 | 2019-2024 | Entyvio |
| Pfizer INC. | $658.37 | 2022-2025 | |
| Lilly USA, LLC | $561.13 | 2024-2025 | Omvoh |
| Genzyme Corporation | $348.75 | 2022-2025 | |
| Celgene Corporation | $348.11 | 2021-2024 | Zeposia |
| Madrigal Pharmaceuticals | $319.00 | 2024-2025 | Rezdiffra, Resmetirom |
| Ardelyx, INC. | $229.23 | 2022-2024 | Ibsrela |
| Janssen Scientific Affairs, LLC | $132.45 | 2023 | Stelara |
| Ethicon US, LLC | $122.69 | 2019 | |
| Merck Sharp & Dohme LLC | $99.85 | 2019-2022 | |
| Regeneron Healthcare Solutions, INC. | $80.08 | 2022-2024 | Dupixent |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironwood Pharmaceuticals, INC | $69.96 | 2022-2024 | |
| Nestle Healthcare Nutrition INC. | $58.84 | 2020-2022 | |
| Intercept Pharmaceuticals, INC. | $57.73 | 2021-2022 | |
| Olympus America INC. | $54.12 | 2024 | Olympus |
| Novo Nordisk INC | $52.53 | 2025 | Wegovy |
| Alfasigma USA, INC. | $51.89 | 2020 | |
| Daiichi Sankyo INC. | $32.17 | 2021 | |
| Amgen INC. | $25.34 | 2023 | Avsola |
| Redhill Biopharma INC. | $18.49 | 2021 | |
| Phathom Pharmaceuticals, INC. | $15.82 | 2024 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saman Chubineh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.